Shared Control: Novel Trial Design Works In COVID, But Will Sponsors Buy In?
COVID-19 has helped demonstrate the viability of platform trials with a shared control arm. That model is easier to extol than it is for sponsors to embrace, especially outside of crisis mode.
You may also be interested in...
Commissioner Hahn’s role in the EUA for convalescent plasma has understandably roiled the world of FDA watchers. But what about the EUA that FDA still has not granted as a treatment for COVID-19?
Duke-Margolis' Mark McClellan touts the advantages networks have over individual operations, citing the dexamethasone RECOVERY trial, and notes need for real-world evidence infrastructure.
Politicization of COVID-19 treatments is one of the unexpected wrinkles amid an unprecedented pandemic. But one lesson from the hydroxychloroquine experience in the US is more typical if still troubling: almost no one followed the rules on reporting follow-up data.